Alnylam Pharmaceuticals, Inc. (ALNY) experienced a positive movement in its stock price, closing at $240.15, which was up by $17.25 or 7.74% at the close of the market. In after-hours trading, the price slightly dipped to $239.60, a decrease of $0.55 or 0.23%. The stock prices surged after the company reported positive top-line results from a late-stage study evaluating Amvuttra (vutrisiran), an investigational RNAi therapeutic, for the treatment of transthyretin-mediated (ATTR) amyloidosis with cardiomyopathy.
Regarding earnings forecasts, Alnylam Pharmaceuticals is expected to report a loss of $1.06 per share next quarter, with estimates ranging from a loss of $1.57 to a loss of $0.36. In comparison to the previous quarter, when the EPS was -$0.52, ALNY has historically surpassed its EPS estimates 75% of the time over the past year, outperforming the industry average of 57.25%.
In terms of sales, ALNY is projected to generate $447.95 million in the next quarter, with estimates varying between $418.20 million and $491.13 million. This forecast follows a previous quarter in which sales totaled $494.33 million. ALNY has consistently exceeded sales estimates 75% of the time in the past year, significantly higher than the industry’s average of 46.67%. Over the last calendar year, Alnylam has outperformed its overall industry in both earnings and sales metrics.
Based on 20 Wall Street analysts offering 12 month price targets for Alnylam Pharma in the last 3 months, the average price target is $251.74 with a high forecast of $400.00 and a low forecast of $159.00. The average price target represents a 4.83% change from the last price of $240.15.
